CureVac
Total Raised
$1.281BInvestors Count
19Deal Terms
8Funding, Valuation & Revenue
17 Fundings
CureVac has raised $1.281B over 17 rounds.
CureVac's latest funding round was a Acq - P2P for on December 18, 2025.
CureVac's valuation in August 2020 was $2,823.36M.
CureVac's latest post-money valuation is from December 2025.
Sign up for a free demo to see CureVac's valuations in December 2025, July 2020 and more.
Date | Round | Amount | Investors | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Revenue | Sources |
|---|---|---|---|---|---|---|
12/18/2025 | Acq - P2P | 4 | ||||
1/29/2021 | PIPE | $450M | Undisclosed Investors | 4 | ||
8/14/2020 | IPO | $213.33M | ▲$2,823.36M | 8 | ||
7/20/2020 | Series G - II | |||||
7/7/2020 | Loan |
CureVac Deal Terms
8 Deal Terms
CureVac's deal structure is available for 8 funding rounds, including their Acq - P2P from December 18, 2025.
Round | Acq - P2P | IPO | Series G - II | Series G | Series F - II |
|---|---|---|---|---|---|
Funding Date | |||||
Pre-Money Valuation | |||||
Post-Money Valuation | |||||
Amount Raised | |||||
Shares Authorized | |||||
Issuance Price | |||||
Dividend Rate | |||||
Liquidation Preferences | |||||
Liquidation Price | |||||
Participation | |||||
Conversion Price | |||||
Anti Dilution | |||||
General Voting | |||||
Board Voting | |||||
Par Value |
Round | Funding Date | Pre-Money Valuation | Post-Money Valuation | Amount Raised | Shares Authorized | Issuance Price | Dividend Rate | Liquidation Preferences | Liquidation Price | Participation | Conversion Price | Anti Dilution | General Voting | Board Voting | Par Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Acq - P2P | |||||||||||||||
IPO | |||||||||||||||
Series G - II | |||||||||||||||
Series G | |||||||||||||||
Series F - II |
CureVac Investors
19 Investors
CureVac has 19 investors. BioNTech invested in CureVac's Acq - P2P funding round.
First funding | Last Funding | Investor | Rounds | Board Seats | Type | Location |
|---|---|---|---|---|---|---|
12/18/2025 | 12/18/2025 | 1 Acq - P2P | Corporation | Germany | ||
7/20/2020 | 7/20/2020 | 1 Series G - II | Corporation | United Kingdom | ||
7/20/2020 | 7/20/2020 | 1 Series G - II | Sovereign Wealth Fund | Qatar | ||
Investment Bank | Luxembourg | |||||
Diversified Financial Services | Germany |
First funding | 12/18/2025 | 7/20/2020 | 7/20/2020 | ||
|---|---|---|---|---|---|
Last Funding | 12/18/2025 | 7/20/2020 | 7/20/2020 | ||
Investor | |||||
Rounds | 1 Acq - P2P | 1 Series G - II | 1 Series G - II | ||
Board Seats | |||||
Type | Corporation | Corporation | Sovereign Wealth Fund | Investment Bank | Diversified Financial Services |
Location | Germany | United Kingdom | Qatar | Luxembourg | Germany |
CureVac Acquisitions
1 Acquisition
CureVac acquired 1 company. Their latest acquisition was Frame Cancer Therapeutics on June 08, 2022.
Date | Investment Stage | Companies | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Total Funding | Note | Sources |
|---|---|---|---|---|---|---|
6/8/2022 | Acquired | 3 |
Date | 6/8/2022 |
|---|---|
Investment Stage | |
Companies | |
Valuation | |
Total Funding | |
Note | Acquired |
Sources | 3 |
Compare CureVac to Competitors
ReCode Therapeutics is a clinical-stage company that develops therapeutics for rare diseases within the biotechnology sector. The company utilizes its SORT lipid nanoparticle platform for the delivery of mRNA and gene correction therapies to various organs and tissues. ReCode Therapeutics serves the healthcare sector, specifically addressing rare and genetically defined diseases. It was founded in 2015 and is based in Menlo Park, California.
Ethris operates as a biotechnology company focused on messenger RNA technology within the pharmaceutical industry. The company specializes in the discovery, design, and development of transcript therapies that aim to restore functions in patients' cells and tissues. Ethris serves the healthcare sector with its focus on disease treatment. It was founded in 2009 and is based in Planegg, Germany.
BioNTech is a biotechnology company that develops immunotherapies to address cancer and infectious diseases. The company works on mRNA-based cancer treatments, immunomodulators, and therapies aimed at improving the immune response. BioNTech also uses its mRNA technology platform to create vaccines for infectious diseases, such as COVID-19. It was founded in 2008 and is based in Mainz, Germany.
Moderna operates as a biotechnology company specializing in messenger ribonucleic acid (mRNA) technology within the healthcare sector. The company focuses on the development of mRNA medicines, including vaccines and therapeutics for various diseases. Moderna's platform enables the rapid design, research, and testing of mRNA-based treatments and vaccines. Moderna was formerly known as Moderna Therapeutics. It was founded in 2010 and is based in Cambridge, Massachusetts.
Arcturus Therapeutics is a commercial mRNA medicines and vaccines company focused on developing therapeutics for liver and respiratory rare diseases and vaccines for infectious diseases. The company provides mRNA therapeutics and vaccines, using LUNAR lipid-mediated delivery and STARR self-amplifying mRNA technologies to create treatments and preventatives for various diseases. Arcturus serves the healthcare sector with RNA-based solutions. It was founded in 2013 and is based in San Diego, California.
Loading...